Stephanie A. Harris - Concepedia

Author

Stephanie A. Harris

Jenner Institute

Also Known As

Brama Hanumunthadu, Gaurav Gupta, Stephanie A. Harris, Stephanie A Harris, Stephanie A. Harris, Stephanie Harris

Publications

11.2K

Citations

H-Index

Concepts

All Affiliations

Jenner Institute University of Oxford London School of Hygiene & Tropical Medicine University of Birmingham University of Cape Town

About

Stephanie A. Harris is an author at Jenner Institute specializing in medicine, vaccination, and immunology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	8	8	2.9K
2	Immunology	7	7	2.9K
3	Health Sciences	1	1	54
4	Biology	1	1	54
5	Cell Biology	1	1	27

Stephanie A. Harris

Publications

10.2K

Citations

H-Index

Page 1

	Year	Citations
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2020	5K
Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial Pedro M. Folegatti, Katie Ewer, Parvinder K. Aley, The Lancet VaccinationVaccine SafetyPhase 1/2Vaccine DevelopmentPreliminary Report	2020	2.6K
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi, The Lancet	2021	1.2K
T-cell activation is an immune correlate of risk in BCG vaccinated infants Helen A. Fletcher, Margaret Ann Snowden, Bernard Landry, Nature Communications	2016	268
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial Iman Satti, Joel N. Meyer, Stephanie A. Harris, The Lancet Infectious Diseases	2014	175
A phase I trial evaluating the safety and immunogenicity of a candidate tuberculosis vaccination regimen, ChAdOx1 85A prime – MVA85A boost in healthy UK adults Morven Wilkie, Iman Satti, Alice Minhinnick, Vaccine	2019	88
Inhibition of Mycobacterial Growth<i>In Vitro</i>following Primary but Not Secondary Vaccination with Mycobacterium bovis BCG Helen A. Fletcher, Rachel Tanner, Robert S. Wallis, Clinical and Vaccine Immunology ImmunodeficienciesTuberculosis PreventionImmunologyImmunodominanceSecondary Vaccination	2013	83
Alternate aerosol and systemic immunisation with a recombinant viral vector for tuberculosis, MVA85A: A phase I randomised controlled trial Zita‐Rose Manjaly Thomas, Iman Satti, Julia L. Marshall, PLoS Medicine	2019	66
Cytomegalovirus infection is a risk factor for tuberculosis disease in infants Julius Müller, Rachel Tanner, Magali Matsumiya, JCI Insight	2019	60
Comparing the safety and immunogenicity of a candidate TB vaccine MVA85A administered by intramuscular and intradermal delivery Joel N. Meyer, Stephanie A. Harris, Iman Satti, Vaccine VaccinologyVaccine SafetyVaccinationVaccine DevelopmentTuberculosis Prevention	2012	56

Page 1